ProstamaxvsGonadorelin (GnRH)

Molecular Formula

C₂₀H₃₃N₅O₉

Molecular Weight

487.5 g/mol

Half-Life

Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through chromatin remodeling at prostate gene promoters; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to short tetrapeptide structure with proline conferring conformational stability

CAS Number

Not publicly registered

Molecular Formula

C₅₅H₇₅N₁₇O₁₃

Molecular Weight

1182.3

Half-Life

2-4 minutes

Bioavailability

Varies by route: ~5-20% (intranasal), 100% (IV/IM injections)

CAS Number

34973-08-5

Common

• Injection site reaction
• Mild fatigue
• Urinary frequency changes
• Mild headache

Uncommon

• Mild pelvic discomfort

Serious

• No documented serious adverse effects

Common

• Mild headache
• Local injection site reactions (redness, swelling)
• Temporary hot flashes
• Mood changes or emotional sensitivity
• Nausea or mild stomach upset
• Allergic skin reactions
• Dizziness or lightheadedness
• Temporary changes in vision
• Joint or muscle aches
• Insomnia or sleep disturbances
• Severe allergic reactions (difficulty breathing, swelling)
• Severe hormonal imbalance symptoms
• Ovarian hyperstimulation syndrome (OHSS)
• Signs of blood clots (chest pain, leg swelling)
• Severe mood changes or depression

Serious

• Severe allergic reaction

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Prostamax (proprietary peptide blend) demonstrates limited published safety data; primarily used in clinical practice based on observational evidence. No serious adverse events reported in clinical use; mild gastrointestinal tolerance issues occasionally reported. Derived from bovine prostatic tissue; potential allergenicity in beef-sensitive individuals requires screening. Quality control and standardization vary across manufacturers.

Contraindications

• xKnown or suspected prostate cancer — potential modulation of prostatic gene expression requires oncological clearance
• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, proline)
• xSevere urinary retention requiring surgical intervention — epigenetic therapy cannot address acute obstruction
• xConcurrent anti-androgen therapy without medical supervision — potential interaction with hormonal mechanisms

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

FDA approved for this use

Safety Overview

Gonadorelin is native GnRH and carries the safety profile established over 40+ years of clinical use in reproductive endocrinology. As the body's natural hormone, it produces minimal local side effects when dosed appropriately. The critical safety concern with gonadorelin is the initial flare effect within 24-48 hours of first dose—temporary elevation in FSH and LH—which can paradoxically suppress sex hormones before the desired stimulation occurs. This flare makes gonadorelin unsuitable for some conditions and explains why synthetic analogs (agonists, antagonists) are preferred in many modern fertility protocols.

Contraindications

• xPregnancy or breastfeeding
• xHormone-sensitive cancers (breast, prostate, ovarian)
• xSevere pituitary or hypothalamic disease
• xUndiagnosed abnormal vaginal bleeding
• xKnown hypersensitivity to GnRH